OTCMTBRIF
Market cap13mUSD
Jan 10, Last price
0.03USD
1D
16.00%
1Q
-11.30%
Name
Therma Bright Inc
Chart & Performance
Profile
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | 2015‑07 | |
Income | ||||||||||
Revenues | 26 9.08% | 24 -82.86% | 139 3,490.70% | |||||||
Cost of revenue | 1,161 | 3,627 | 5,824 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,135) | (3,603) | (5,685) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 1 | |||||||||
Tax Rate | ||||||||||
NOPAT | (1,135) | (3,603) | (5,686) | |||||||
Net income | (2,451) -34.94% | (3,768) -35.93% | (5,881) -31.70% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,000 | 5,311 | ||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 65 | 65 | 20 | |||||||
Long-term debt | 25 | 76 | 161 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (2,029) | (881) | (3,106) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (1,009) | (2,175) | (3,800) | |||||||
CAPEX | (268) | |||||||||
Cash from investing activities | (138) | (691) | (205) | |||||||
Cash from financing activities | 966 | (34) | 5,306 | |||||||
FCF | (1,288) | (1,980) | (5,710) | |||||||
Balance | ||||||||||
Cash | 1 | 182 | 3,082 | |||||||
Long term investments | 2,119 | 840 | 205 | |||||||
Excess cash | 2,119 | 1,021 | 3,280 | |||||||
Stockholders' equity | (12,962) | (13,943) | 2,747 | |||||||
Invested Capital | 14,352 | 14,078 | 111 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 315,916 | 242,840 | 228,454 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (1,036) | (3,528) | (5,533) | |||||||
EV/EBITDA | ||||||||||
Interest | 9 | 13 | 1 | |||||||
Interest/NOPBT |